{"entity":{"id":"itgb3","kind":"target","name":"ITGB3","aka":["integrin subunit beta 3","Integrin beta-3","CD61","GPIIIa","GP3A"],"tldr":"ITGB3 (Integrin beta-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","summary":"Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor (VWF). Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognise the sequence R-G-D in a wide array of ligands.\n\nOpen Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes clinical 0.50, affected pathway 0.97, literature 0.97, genetic association 0.00, animal model 0.52).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:6156","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6156"},{"label":"UniProt P05106","url":"https://www.uniprot.org/uniprotkb/P05106/entry"},{"label":"NCBI Gene 3690","url":"https://www.ncbi.nlm.nih.gov/gene/3690"},{"label":"Ensembl ENSG00000259207","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000259207"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.50. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"ITGB3","role":["drug-target"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:6156","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6156","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P05106","url":"https://www.uniprot.org/uniprotkb/P05106/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000259207","url":"https://platform.opentargets.org/target/ENSG00000259207/associations","note":"association with cancer (MONDO_0004992) 0.68;  (GraphQL API, CC0)"}],"distribution":"not-established","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ITGB3: RNA tissue enhanced (blood vessel 38 nTPM, thyroid gland 53 nTPM); blood lineage lineage enriched (granulocytes 6 nTPM); high antibody staining in 1 normal tissue; highest cancer staining renal cancer (1 of 12 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas ITGB3 tissue","url":"https://www.proteinatlas.org/ENSG00000259207-ITGB3/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000259207 associations","url":"https://platform.opentargets.org/target/ENSG00000259207/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:6156","ensembl":"ENSG00000259207","uniprot":"P05106","entrez":"3690","firstDescribed":1987,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Fitzgerald L.A. et al, J. Biol. Chem, 1987, \"Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to 'integrin'\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/3494014/","biology":"Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor (VWF). Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognise the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognises the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Location: Cell membrane; Cell projection, lamellipodium membrane; Cell junction, focal adhesion; Postsynaptic cell membrane (UniProt). Locus 17q21.32 (HGNC).","whereFound":[],"targetClass":"other","prevalence":[]},"route":"/targets/itgb3/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}]}}